Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 16, 2026Journal of Translational Internal MedicineOpen Access

Inflammation, metabolism, and aging in heart failure with preserved ejection fraction: Mechanisms and treatment perspectives

View Full Paper
Ask AI
Bookmark
Share

Key result

Interconnected inflammation-metabolism-aging axis drives HFpEF pathogenesis and offers novel therapeutic targets.

Why the study?

Heart failure with preserved ejection fraction is an increasingly prevalent syndrome with limited effective therapies, representing a major unmet need in cardiovascular medicine.

Design

Review

Authors

YTYaqun TengWBWeikang BianQLQi Li

Discussion

Loading...

Member takes

Overview

Does not support immediate practice changes in HFpEF; leaves open targeted trials of inflammation-metabolism-aging therapies.

Key Points

  • The aim is to elucidate the relationship between inflammation, metabolism, and aging in heart failure with preserved ejection fraction (HFpEF).
  • Review of key advances in the understanding of HFpEF pathogenesis.
  • Discussion of systemic inflammation, metabolic dysregulation, and cellular senescence.
  • Integration of therapeutic approaches targeting identified pathways.
  • Identified a common link between systemic proinflammatory states and metabolic disorders in HFpEF.
  • Highlighted the role of microvascular inflammation in the disease's progression.
  • Proposed new therapeutic strategies based on mechanistic insights into inflammation and metabolism.

Structured PICO

P
Population
Patients with heart failure with preserved ejection fraction (HFpEF)

This review provides a conceptual framework linking systemic inflammation, metabolic dysregulation, and aging to guide therapeutic development for HFpEF.

Cite This Study

Teng et al. (2026) conducted a review in Heart failure with preserved ejection fraction (HFpEF). An interconnected inflammation-metabolism-aging axis plays a central role in the pathogenesis of heart failure with preserved ejection fraction, offering new targets for therapeutic development.

synapsesocial.com/papers/6a315300d80eb74207c76d43https://doi.org/10.1515/jtim-2026-0043
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction2024 · 51 citations
  2. 2Epigenetic Regulation of Aging and its Rejuvenation2025
  3. 3SGLT2 inhibition eliminates senescent cells and alleviates pathological aging2024 · 139 citations
  4. 4Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity2024 · 945 citations
  5. 5Intermittent fasting and cardiovascular health: a circadian rhythm-based approach2025 · 24 citations